Zenith Drugs Limited (NSE:ZENITHDRUG)

Market Cap	805.99M -49.5%
Revenue (ttm)	1.44B +10.0%
Net Income	37.77M -61.0%
EPS	2.20 +30.4%
Shares Out	17.15M
PE Ratio	21.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,400
Average Volume	11,200
Open	46.00
Previous Close	47.00
Day's Range	46.00 - 47.75
52-Week Range	45.00 - 107.00
Beta	1.38
RSI	41.47
Earnings Date	Feb 13, 2026

About Zenith Drugs

Zenith Drugs Limited, together with its subsidiaries, manufactures and trades in branded, generic, and OTC medicines. The company offers a range of pharmaceutical formulations, such as ORS powder, liquid orals, ointments, creams, gels, liquid externals, capsules, and tablets. Its products are indicated for allergology, general analytics, infections, genetics, endocrinology, and microbiology. The company operates in India, Costa Rica, Mauritius, Cambodia, Myanmar, Yemen, Sierra, Leone, Liberia, and Bhutan. Zenith Drugs Limited was incorporated i...

• Industry: Pharmaceutical Preparations
• Founded: 1956
• Employees: 182
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZENITHDRUG

Financial Performance

In fiscal year 2025, Zenith Drugs's revenue was 1.33 billion, an increase of 1.29% compared to the previous year's 1.32 billion. Earnings were 71.61 million, a decrease of -24.92%.